Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 6, 2014, Pages 466-477

  Hibbitts, A ^a   O'mahony, A M ^b   Forde, E ^a   Nolan, L ^a   Ogier, J ^c   Desgranges, S ^c   Darcy, R ^c   Macloughlin, R ^d   O'driscoll, C M ^b   Cryan, S A ^a,e  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d Aerogen Ltd   (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Calu 3 cells; high throughput screening; nonviral gene delivery; RNAi; vibrating mesh nebulizer

Indexed keywords

CYCLODEXTRIN; LUCIFERASE; NANOCOMPLEX; PROPYLAMINE; SC12CDCLICKPROPYLAMINE; SMALL INTERFERING RNA; SODIUM CHLORIDE; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN DERIVATIVE; NANOPARTICLE;

ARTICLE; BRONCHUS MUCOSA; CELL LINE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NEBULIZATION; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; ZETA POTENTIAL; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; NEBULIZER; PROCEDURES; REPORTER GENE; RNA INTERFERENCE; TIME;

ADMINISTRATION, INHALATION; BETA-CYCLODEXTRINS; CELL LINE; GENE EXPRESSION REGULATION; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUCIFERASES; NANOPARTICLES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION;

EID: 84915774623     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1045     Document Type: Article

References (54)

1. de Fougerolles A, and Novobrantseva T: siRNA and the lung: research tool or therapeutic drug?. Curr Opin Pharmacol. 2008;8:280-285
2. Taratula O, Garbuzenko OB, Chen AM, and Minko T: Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19:900-914
3. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, and Chen J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A. 2004;101:8676-8681
4. Seong J-H, Lee K-M, Kim ST, Jin S-E, and Kim C-K: Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. J Gene Med. 2006;8:314-323
5. Birchall J: Pulmonary delivery of nucleic acids. Expert Opin Drug Deliv. 2007;4:575-578
6. Weiss DJ: Delivery of DNA to lung airway epithelium. Methods Mol Biol. 2004;246:53-68
7. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, and MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457-462
8. Aneja MK, Geiger J-P, Himmel A, and Rudolph C: Targeted gene delivery to the lung. Expert Opin Drug Deliv. 2009;6:567-583
9. Whitehead KA, Langer R, and Anderson DG: Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-138
10. Patton JS, and Byron PR: Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67-74
11. Kichler A: Gene transfer with modified polyethylenimines. J Gene Med. 2004;6:S3-S10
12. Kircheis R, Wightman L, and Wagner E: Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev. 2001;53:341-358
13. Hibbitts A, Lieggi N, McCabe O, Thomas W, Barlow J, O'Brien F, and Cryan S-A: Screening of siRNA nanoparticles for delivery to airway epithelial cells using highcontent analysis. Ther Deliv. 2011;2:987-999
14. Godbey WT, and Mikos AG: Recent progress in gene delivery using non-viral transfer complexes. J Control Release. 2001;72:115-125
15. Plank C, Mechtler K, Szoka FC Jr, and Wagner E: Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996;7:1437-1446
16. O'Mahony AM, Ogier J, Desgranges S, Cryan JF, Darcy R, and O'Driscoll CM: A click chemistry route to 2-functionalised PEGylated and cationic b-cyclodextrins: co-formulation opportunities for siRNA delivery. Org Biomol Chem. 2012;10:4954-4960
17. O'Mahony AM, Godinho BM, Ogier J, Devocelle M, Darcy R, Cryan JF, and O'Driscoll CM: Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery. ACS Chem Neurosci. 2012;3:744-752
18. Tewes F, Brillault J, Couet W, and Olivier J-C: Formulation of rifampicin-cyclodextrin complexes for lung nebulization. J Control Release. 2008;129:93-99
19. Thi THH, Azaroual N, and Flament M-P: Characterization and in vitro evaluation of the formoterol/cyclodextrin complex for pulmonary administration by nebulization. Eur J Pharm Biopharm. 2009;72:214-218
20. Salem LB, Bosquillon C, Dailey LA, Delattre L, Martin GP, Evrard B, and Forbes B: Sparing methylation of bcyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro. J Control Release. 2009;136:110-116
21. Cabral-Marques H, and Almeida R: Optimisation of spraydrying process variables for dry powder inhalation (DPI) formulations of corticosteroid/cyclodextrin inclusion complexes. Eur J Pharm Biopharm. 2009;73:121-129
22. Zhang Y, Jiang XG, and Yao J: Nasal absorption enhancement of insulin by sodium deoxycholate in combination with cyclodextrins. Acta Pharmacol Sin. 2001; 22:1051-1056
23. Jalalipour M, Najafabadi AR, Gilani K, Esmaily H, and Tajerzadeh H: Effect of dimethyl-b-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. J Pharm Sci. 2008;97: 5176-5185
24. Chaturvedi K, Ganguly K, Kulkarni AR, Kulkarni VH, Nadagouda MN, Rudzinski WE, and Aminabhavi TM: Cyclodextrin-based siRNA delivery nanocarriers: a state-of-Theart review. Expert Opin Drug Deliv. 2011;8:1455-1468
25. Mellet CO, Fernandez JMG, and Benito JM: Cyclodextrinbased gene delivery systems. Chem Soc Rev. 2011;40: 1586-1608
26. Loftsson T, Jarho P, Másson M, and Järvinen T: Cyclodextrins in Drug delivery. Expert Opin Drug Deliv. 2005; 2:335-351
27. O'Mahony AM, O'Neill MJ, Godinho BMDC, Darcy R, Cryan J, and O'Driscoll C: Cyclodextrins for non-viral gene and siRNA delivery Pharm Nanotechnol. 2013;1:6-14
28. Klein B, Worndl K, Lutz-Meindl U, and Kerschbaum HH: Perturbation of intracellular K+ homeostasis with valinomycin promotes cell death by mitochondrial swelling and autophagic processes. Apoptosis. 2011;16:1101-1117
29. Lofrumento D, La Piana G, Abbrescia D, Palmitessa V, La Pesa V, Marzulli D, and Lofrumento NE: Valinomycin induced energy-dependent mitochondrial swelling, cytochrome c release, cytosolic NADH/cytochrome c oxidation and apoptosis. Apoptosis. 2011;16:1004-1013
30. Lee DH, and Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998;8:397-403
31. Han YH, and Park WH: MG132, a proteasome inhibitor decreased the growth of Calu-6 lung cancer cells via apoptosis and GSH depletion. Toxicol In Vitro. 2010;24:1237-1242
32. Heyder J: Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc. 2004;1: 315-320
33. O'Mahony AM, Doyle D, Darcy R, Cryan JF, and O'Driscoll CM: Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: effect of reversing primary and secondary face modifications. Eur J Pharm Sci. 2012;47:896-903
34. O'Mahony A, Desgranges S, Ogier J, Quinlan A, Devocelle M, Darcy R, Cryan J, and O'Driscoll C: In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery. Pharm Res. 2012;1-13
35. Steele TWJ, Zhao X, Tarcha P, and Kissel T: Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery. Eur J Pharm Biopharm. 2012;80:14-24
36. Tsapis N, Bennett D, Jackson B, Weitz DA, and Edwards DA: Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A. 2002; 99:12001-12005
37. O'Mahony AM, Ogier J, Darcy R, Cryan JF, and O'Driscoll CM: Cationic and PEGylated amphiphilic cyclodextrins: co-formulation opportunities for neuronal siRNA delivery. PLoS ONE. 2013;8:e66413
38. Rawlinson LA, O'Brien PJ, and Brayden DJ: High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. J Control Release. 2010;146:84-92
39. Lawlor C, O'Sullivan MP, Sivadas N, O'Leary S, Gallagher PJ, Keane J, and Cryan S-A: The application of highcontent analysis in the study of targeted particulate delivery systems for intracellular drug delivery to alveolar macrophages. Mol Pharm. 2011;8:1100-1112
40. Rejman J, Bragonzi A, and Conese M: Role of clathrin- And caveolae-mediated endocytosis in gene transfer mediated by lipo- And polyplexes. Mol Ther. 2005;12:468-474
41. von Gersdorff K, Sanders NN, Vandenbroucke R, De Smedt SC, Wagner E, and Ogris M: The internalization route resulting in successful gene expression Depends on both cell line and polyethylenimine polyplex type. Mol Ther. 2006;14:745-753
42. Matilainen L, Toropainen T, Vihola H, Hirvonen J, Järvinen T, Jarho P, and Järvinen K: In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J Control Release. 2008;126:10-16
43. Arima H, Tsutsumi T, Yoshimatsu A, Ikeda H, Motoyama K, Higashi T, Hirayama F, and Uekama K: Inhibitory effect of siRNA complexes with polyamidoamine dendrimer/acyclodextrin conjugate (generation 3, G3) on endogenous gene expression. Eur J Pharm Sci. 2011;44:375-384
44. Sporty JL, Horalkova L, and Ehrhardt C: In vitro cell culture models for the assessment of pulmonary drug disposition. Expert Opin Drug Metab Toxicol. 2008;4:333-345
45. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, and Kay MA: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537-541
46. Yi R, Doehle BP, Qin Y, Macara IG, and Cullen BR: Overexpression of Exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA. 2005;11:220-226
47. Castanotto D, Sakurai K, Lingeman R, Li H, Shively L, Aagaard L, Soifer H, Gatignol A, Riggs A, and Rossi JJ: Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 2007;35:5154-5164
48. Lee DW, Yun K-S, Ban H-S, Choe W, Lee SK, and Lee KY: Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release. 2009;139:146-152
49. Raviña M, Cubillo E, Olmeda D, Novoa-Carballal R, Fernandez-Megia E, Riguera R, Sánchez A, Cano A, and Alonso M: Hyaluronic acid/chitosan-g-poly(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery. Pharm Res. 2010;27:2544-2555
50. Malek A, Czubayko F, and Aigner A: PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target. 2008;16:124-139
51. Bartlett D, Su H, Hildebrandt I, Weber W, and Davis ME: Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A. 2007;104:15549-15554
52. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, and Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005;65:8984-8992
53. Bartlett DW, and Davis ME: Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng. 2008;99:975-985
54. Yang W, Chow KT, Lang B, Wiederhold NP, Johnston KP, and Williams RO 3rd: In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. Eur J Pharm Sci. 2010;39:336-347